S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine

Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalal, Jamshed, Mohan, J. C., Iyengar, S. S., Hiremath, Jagdish, Sathyamurthy, Immaneni, Bansal, Sandeep, Kahali, Dhiman, Dasbiswas, Arup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985099/
https://www.ncbi.nlm.nih.gov/pubmed/29887996
http://dx.doi.org/10.1155/2018/8681792
Descripción
Sumario:Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review.

Ejemplares similares